SHANNON ROSE PETROSKE NP
Prescription History 1962854075
Nurse Practitioner - Family in Hibbing, MN


Quality Rating: 90.32 out of 100 score

NPI Status: Active since July 13, 2016

Contact Information

750 E 34TH ST
HIBBING, MN
ZIP 55746
Phone: (218) 362-6898

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SHANNON ROSE PETROSKE NP, an active Family specialist practicing in Hibbing, MN. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 180 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 91 claims alone.

Medication Index

No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 91
30-Day Fills 201.0
Days Supply 5,987
MN State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills143.8
Peer Average Days Supply4,278
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 56.9% higher than the standard regional baseline profile for MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,658.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$40.20

State Avg Cost Per Claim

$33.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.0
Days Supply 990
MN State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills48.5
Peer Average Days Supply1,440
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,220.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$383.69

State Avg Cost Per Claim

$294.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 22.0
Days Supply 615
MN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills67.1
Peer Average Days Supply1,966
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.9% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $270.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.88

State Avg Cost Per Claim

$33.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Letrozole

Generic Formulation: LetrozoleSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 62
30-Day Fills 152.1
Days Supply 4,563
MN State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills119.2
Peer Average Days Supply3,547
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 26.5% more claims than the standard regional baseline profile for MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,592.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$90.20

State Avg Cost Per Claim

$34.21

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SHANNON ROSE PETROSKE NP provides transparency into local medical care patterns within Hibbing, MN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.